First National Trust’s Axsome Therapeutics AXSM Stock Holding History

First National Trust’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,412	Closed	-$238K	–	380
2023 Q3	$238K	Hold	3,412	–	–	0.01%	339
2023 Q2	$245K	Sell	3,412 -1,000	-23%	-$73.8K	0.01%	336
2023 Q1	$272K	Sell	4,412 -2,900	-40%	-$191K	0.01%	327
2022 Q4	$564K	Hold	7,312	–	–	0.03%	247
2022 Q3	$326K	Hold	7,312	–	–	0.02%	292
2022 Q2	$280K	Hold	7,312	–	–	0.02%	310
2022 Q1	$303K	Hold	7,312	–	–	0.02%	321
2021 Q4	$276K	Hold	7,312	–	–	0.01%	330
2021 Q3	$241K	Hold	7,312	–	–	0.01%	325
2021 Q2	$493K	Hold	7,312	–	–	0.03%	262
2021 Q1	$414K	Buy	+7,312	New	+$514K	0.03%	271

Other funds holding AXSM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return